Regulation of mast cell characteristics by cytokines: divergent effects of interleukin-4 on immature mast cell lines versus mature human skin mast cells.
Mast cells (MC) are of hematopoietic origin but complete their differentiation exclusively within tissues. The mediators that positively or negatively affect the maturation process are incompletely defined. Here, the human MC line HMC-1 (subclone 5C6) was used along with several treatments (IL-4, IL-6, NGFbeta), either alone or in combination, and MC differentiation was monitored by flow-cytometric analysis of c-kit, tryptase, and FcepsilonRIalpha expression. Of the different treatments, IL-4 displayed the clearest effects by suppressing the expression of the three markers and inhibiting cellular growth, while the other cytokines had no (NGFbeta) or negligible (IL-6) effects only. The downregulating effects of IL-4 could not be overcome by any other treatment. There is some controversy in the literature as to the impact of IL-4 on the MC lineage. To determine whether the effects from IL-4 were differentiation stage dependent, two further human MC subsets (skin MC and LAD 2 cells) were investigated. No effects on c-kit and FcepsilonRIalpha expression were noted when terminally differentiated skin MC were used as target cells, while a modest downregulation of c-kit was observed with intermediately matured LAD 2 cells. In sharp contrast to HMC-1 5C6 cells, the survival of skin MC was significantly enhanced by IL-4 treatment. Our data therefore imply that at a lower maturation stage, IL-4 acts as a negative regulator of the MC lineage, but that this property disappears or is even reversed upon terminal differentiation of the cell. Our study provides direct proof that the effects of IL-4 vary substantially in the course of MC maturation.
Department of Dermatology and Allergy, University Medicine Berlin, Charité Campus Mitte, Schumannstr. 20/21, 10117 Berlin, Germany.
Friedrich
F
Thienemann
Beate M
BM
Henz
Magda
M
Babina
D015703:Antigens, CD / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects / Q000276:immunology; D019070:Cell Lineage; D005434:Flow Cytometry; D006801:Humans; D015847:Interleukin-4 / Q000494:pharmacology*; D015850:Interleukin-6 / Q000494:pharmacology; D008407:Mast Cells / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism*; D020932:Nerve Growth Factor / Q000494:pharmacology; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism; D017452:Receptors, IgG / Q000378:metabolism; D012697:Serine Endopeptidases / Q000378:metabolism; D012867:Skin / Q000166:cytology* / Q000276:immunology; D053802:Tryptases
D015703:Antigens, CD; C080568:Fc gamma receptor IIA; D015850:Interleukin-6; D017452:Receptors, IgG; D015847:Interleukin-4; D020932:Nerve Growth Factor; D019009:Proto-Oncogene Proteins c-kit; D012697:Serine Endopeptidases; D053802:Tryptases